Cue Biopharma, Inc. (CUE) — insider trading
Health Care · Nasdaq
Cue Biopharma, Inc. (CUE) has 13 reported SEC Form 4 insider transactions in our data (latest 2026-07-13).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-13 | Borie Dominique Christian | Officer (Chief Medical Officer), Other | Grant / award / vesting (derivative) | 63,000 | $0.00 | $0 | Form 4 |
| 2026-07-13 | Borie Dominique Christian | Officer (Chief Medical Officer), Other | Grant / award / vesting | 31,500 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 327,537 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 327,537 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Ray Sumita | Officer (Chief Legal Compliance Officer), Other | Grant / award / vesting (derivative) | 54,589 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Ray Sumita | Officer (Chief Legal Compliance Officer), Other | Grant / award / vesting | 54,589 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Meluzio Michael Vincent | Officer (VP, Prin. Accounting Officer) | Grant / award / vesting (derivative) | 40,942 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Meluzio Michael Vincent | Officer (VP, Prin. Accounting Officer) | Grant / award / vesting | 40,942 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Meehan Viola Mong | Director | Grant / award / vesting | 21,800 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Sarraf Pasha | Director | Grant / award / vesting | 21,800 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Camardo Daniel A. | Director | Grant / award / vesting | 21,800 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Garzone Pamela | Director | Grant / award / vesting | 21,800 | $0.00 | $0 | Form 4 |
| 2026-05-30 | Camardo Daniel A. | Director | Grant / award / vesting (derivative) | 1,626 | $0.00 | $0 | Form 4 |
Ask the chat about CUE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Cue Biopharma, Inc. (CUE).
Last updated 2026-07-13 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.